These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18541345)

  • 1. The metabolism of CYP2C9 and CYP2C19 for gliclazide by homology modeling and docking study.
    Yao Y; Han WW; Zhou YH; Li ZS; Li Q; Chen XY; Zhong DF
    Eur J Med Chem; 2009 Feb; 44(2):854-61. PubMed ID: 18541345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: molecular dynamics simulation and docking studies.
    Banu H; Renuka N; Vasanthakumar G
    Biochimie; 2011 Jun; 93(6):1028-36. PubMed ID: 21356265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects.
    Kang P; Cho CK; Jang CG; Lee SY; Lee YJ; Choi CI; Bae JW
    Arch Pharm Res; 2023 May; 46(5):438-447. PubMed ID: 37097441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between CYP2C9 and CYP2C19 in reconstituted binary systems influence their catalytic activity: possible rationale for the inability of CYP2C19 to catalyze methoxychlor demethylation in human liver microsomes.
    Hazai E; Kupfer D
    Drug Metab Dispos; 2005 Jan; 33(1):157-64. PubMed ID: 15486075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination.
    Elliot DJ; Suharjono ; Lewis BC; Gillam EM; Birkett DJ; Gross AS; Miners JO
    Br J Clin Pharmacol; 2007 Oct; 64(4):450-7. PubMed ID: 17517049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers.
    Shao H; Ren XM; Liu NF; Chen GM; Li WL; Zhai ZH; Wang DW
    J Clin Pharm Ther; 2010 Jun; 35(3):351-60. PubMed ID: 20831536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.
    Klose TS; Ibeanu GC; Ghanayem BI; Pedersen LG; Li L; Hall SD; Goldstein JA
    Arch Biochem Biophys; 1998 Sep; 357(2):240-8. PubMed ID: 9735164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
    Wester MR; Lasker JM; Johnson EF; Raucy JL
    Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.
    Rosemary J; Surendiran A; Rajan S; Shashindran CH; Adithan C
    Indian J Med Res; 2006 May; 123(5):665-70. PubMed ID: 16873909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.
    Zhang Y; Si D; Chen X; Lin N; Guo Y; Zhou H; Zhong D
    Br J Clin Pharmacol; 2007 Jul; 64(1):67-74. PubMed ID: 17298483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.
    Shon JH; Yoon YR; Kim MJ; Kim KA; Lim YC; Liu KH; Shin DH; Lee CH; Cha IJ; Shin JG
    Br J Clin Pharmacol; 2005 May; 59(5):552-63. PubMed ID: 15842554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors.
    Suzuki H; Kneller MB; Rock DA; Jones JP; Trager WF; Rettie AE
    Arch Biochem Biophys; 2004 Sep; 429(1):1-15. PubMed ID: 15288804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
    Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
    Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach.
    Venkatakrishnan K; von Moltke LL; Greenblatt DJ
    J Pharm Sci; 1998 Jul; 87(7):845-53. PubMed ID: 9649353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselective hexobarbital 3'-hydroxylation by CYP2C19 expressed in yeast cells and the roles of amino acid residues at positions 300 and 476.
    Saito K; Dan H; Masuda K; Katsu T; Hanioka N; Yamamoto S; Miyano K; Yamano S; Narimatsu S
    Chirality; 2007 Jul; 19(7):550-8. PubMed ID: 17487889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C19 polymorphisms account for inter-individual variability of drug metabolism in cynomolgus macaques.
    Uno Y; Matsushita A; Shukuya M; Matsumoto Y; Murayama N; Yamazaki H
    Biochem Pharmacol; 2014 Sep; 91(2):242-8. PubMed ID: 25036290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and energetic analysis to provide insight residues of CYP2C9, 2C11 and 2E1 involved in valproic acid dehydrogenation selectivity.
    Bello M; Mendieta-Wejebe JE; Correa-Basurto J
    Biochem Pharmacol; 2014 Jul; 90(2):145-58. PubMed ID: 24794636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of enzyme selectivity in the human CYP2C subfamily: homology modelling of CYP2C8, CYP2C9 and CYP2C19 from the CYP2C5 crystallographic template.
    Lewis DF; Dickins M; Lake BG; Goldfarb PS
    Drug Metabol Drug Interact; 2003; 19(4):257-85. PubMed ID: 14768974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
    Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
    Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.